On November 23, a press conference was held in Moscow dedicated to the start of the XVII contest of pharmaceutical industry professionals Platinum Ounce 2016.
The event was attended by the heads of companies and institutes that joined the organizing committee of the contest this year: the chairman of the contest’s organizing committee, the director of the Institute for Public Health Development Yuri Krestinsky, the editor-in-chief of the Pharmaceutical Gazette Herman Inozemtsev, the IMS general director Nikolai Demidov, General Director of Alpharm Anna Ermolaeva, General Director of DSM Group Sergey Shulyak and the Director of Health Research of Ipsos Healthcare Oleg Feldman.
The contest includes the following main categories:
Project of the Year with sub-categories Business Project, Social Project and Digital Project;
Dynamics of the year, in which the fastest growing companies will be represented;
Launch of the Year, marking the best launch of new drugs in the market;
Drug of the Year, with sub-categories Generic Drug, OTC Drug and Original Drug;
Pharmacy of the Year as an individual institution (physical entity). The winner is nominated by the Pharmaceutichesky vestnik.
Also, the Company of the Year will be nominated, with two sub-nominations Drug Manufacturer and Drug Distributor.
The experts vote in two phases. The first phase will begin one of these days, and will be completed in the end of February of the approaching year. “In fact, our method is almost the same as the method used by the American Film Academy in determining the winners of the Oscar,” Mr. Krestinsky said. “Let’s hope this is not the worst comparison.”
UPD: General Director of IMS Nikolay Demidov described the trends in the pharmaceutical market. In his opinion, there exists a negative macroeconomic background currently, which is diluted by the illusion of stability of the last three quarters. The real disposable incomes of the population are declining and people can buy fewer goods that are getting more expensive. However, there are some positive trends, such as the potential for two-figures growth of the retail segment in the third quarter.
According to the General Director of DSM Group Sergei Shulyak, the recently received data for the III quarter show a positive trend in sales of pharmaceutical products (+ 5%), which gives hope for a positive result by the end of the year. According to his forecast, the market will grow by no more than 7% in rubles, both in 2016 and 2017. “However, this does not correspond to the rate of growth that we would like to see,” he admitted. “Everyone is used to getting double-digit growth rates, but now we need to think about how to develop further, how to position ourselves and how to move forward.”
Alpharm’s General Director Anna Ermolaeva analyzed the structure of the market and noted that the division of the market into the state and retail segments has not changed: the retail segment of 68% and the state segment of 32%. However, she predicts the growth of the state segment of the market (in packages) compared to 2015.
In addition, she noted that in the area of public procurement, the distribution segment is being consolidated: the number of suppliers has decreased by 10%. The share of imported drugs in the structure of shipments has increased. These trends will continue in 2017, according to Ms. Ermolayeva.
The Director of Health Research in Ipsos Healthcare Oleg Feldman drew his colleagues’ attention to digital technologies. He recalled that Donald Trump, who won the elections in the United States, despite his considerable age, used these technologies 2 or 3 times more actively than Hillary Clinton.
It should be noted that this year the executive management of the competition is represented by the communication agency Aaron Lloyd Media, and RXCode is the organizer of the award ceremony.
On November 23, a press conference was held in Moscow dedicated to the start of the XVII contest of pharmaceutical industry professionals Platinum Ounce 2016.
The event was attended by the heads of companies and institutes that joined the organizing committee of the contest this year: the chairman of the contest’s organizing committee, the director of the Institute for Public Health Development Yuri Krestinsky, the editor-in-chief of the Pharmaceutical Gazette Herman Inozemtsev, the IMS general director Nikolai Demidov, General Director of Alpharm Anna Ermolaeva, General Director of DSM Group Sergey Shulyak and the Director of Health Research of Ipsos Healthcare Oleg Feldman.
The contest includes the following main categories:
Also, the Company of the Year will be nominated, with two sub-nominations Drug Manufacturer and Drug Distributor.
The experts vote in two phases. The first phase will begin one of these days, and will be completed in the end of February of the approaching year. “In fact, our method is almost the same as the method used by the American Film Academy in determining the winners of the Oscar,” Mr. Krestinsky said. “Let’s hope this is not the worst comparison.”
UPD: General Director of IMS Nikolay Demidov described the trends in the pharmaceutical market. In his opinion, there exists a negative macroeconomic background currently, which is diluted by the illusion of stability of the last three quarters. The real disposable incomes of the population are declining and people can buy fewer goods that are getting more expensive. However, there are some positive trends, such as the potential for two-figures growth of the retail segment in the third quarter.
According to the General Director of DSM Group Sergei Shulyak, the recently received data for the III quarter show a positive trend in sales of pharmaceutical products (+ 5%), which gives hope for a positive result by the end of the year. According to his forecast, the market will grow by no more than 7% in rubles, both in 2016 and 2017. “However, this does not correspond to the rate of growth that we would like to see,” he admitted. “Everyone is used to getting double-digit growth rates, but now we need to think about how to develop further, how to position ourselves and how to move forward.”
Alpharm’s General Director Anna Ermolaeva analyzed the structure of the market and noted that the division of the market into the state and retail segments has not changed: the retail segment of 68% and the state segment of 32%. However, she predicts the growth of the state segment of the market (in packages) compared to 2015.
In addition, she noted that in the area of public procurement, the distribution segment is being consolidated: the number of suppliers has decreased by 10%. The share of imported drugs in the structure of shipments has increased. These trends will continue in 2017, according to Ms. Ermolayeva.
The Director of Health Research in Ipsos Healthcare Oleg Feldman drew his colleagues’ attention to digital technologies. He recalled that Donald Trump, who won the elections in the United States, despite his considerable age, used these technologies 2 or 3 times more actively than Hillary Clinton.
It should be noted that this year the executive management of the competition is represented by the communication agency Aaron Lloyd Media, and RXCode is the organizer of the award ceremony.
Read more: http://www.pharmvestnik.ru/publs/lenta/v-rossii/startoval-konkurs-farmotrasli-platinovaja-untsija-2016.html